Details About Generic Salt ::  Nalidixi

Main Medicine Class:: Urinary anti-infective   

(nal-ih-DIK-sik acid)

NegGram

Class: Urinary anti-infective

Drugs Class ::

 Action Interferes with DNA formation of certain bacteria.

Indications for Drugs ::

 Indications Treatment of UTIs caused by susceptible gram-negative bacteria, including most Proteus strains, Klebsiella and Enterobacter species and E. coli.

Drug Dose ::

 Route/Dosage

ADULTS: PO Initial therapy: 1 g qid for 1 or 2 wk. Prolonged Therapy: 1 g bid after initial therapy. Children 3 mo to 2 YR: PO Initial therapy: 55 mg/kg/day divided into 4 equal doses. Prolonged Therapy: 33 mg/kg/day in 4 divided doses after initial therapy.

Contraindication ::

 Contraindications History of seizures.

Drug Precautions ::

 Precautions

Pregnancy: Pregnancy category undetermined. Do not use during first trimester. Lactation: Excreted in breast milk. Children: Use drug with caution in prepubertal children; may affect cartilage and joints. CNS effects: Convulsions, increased intracranial pressure and toxic psychosis may occur with overdose or predisposing factors (eg, epilepsy, cerebral arteriosclerosis). Hematologic: Can produce clinically significant hemolysis in patients with G-6-PD deficiency. Renal failure: Patients with compromised renal function may fail to accumulate nalidixic acid, decreasing its effectiveness.

Drug Side Effects ::

 Adverse Reactions

CNS: Drowsiness; weakness; headache; dizziness; vertigo; seizures; intracranial hypertension; increased intracranial pressure; sixth cranial nerve palsy in children and infants. DERM: Rash; pruritus; urticaria; angioedema; photosensitivity. EENT: Visual disturbances. GI: Abdominal pain; nausea; vomiting; diarrhea. HEMA: Thrombocytopenia; leukopenia, eosinophilia or hemolytic anemia (associated with G-6-PD deficiency or acute nalidixi reaction). HEPA: Cholestatic jaundice; cholestasis. META: Metabolic acidosis.

Drug Mode of Action ::  

 Action Interferes with DNA formation of certain bacteria.

Drug Interactions ::

 Interactions

Oral anticoagulants: May enhance anticoagulant effect.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Obtain baseline assessments of burning/pain with urination, urinary urgency or frequency, level of consciousness.
• Assess for adverse reactions, primarily with CNS and GI systems.
• Obtain urine specimens as needed for culture and sensitivity.
• Monitor blood counts, liver and renal function test values if treatment is continued longer than 2 wk.
• Re-evaluate patient for improvement of symptoms.

Drug Storage/Management ::

 Administration/Storage

• Give medication ³ 1 hr before meals.
• Shake suspension well before use.
• Store in tightly-closed container at room temperature. Do not freeze.

Drug Notes ::

 Patient/Family Education

• Tell patient to take with food or milk.
• Explain importance of adequate hydration and encourage intake of 1500 to 3000 mL fluids/day, unless otherwise specified by physician.
• Instruct patient to report the following symptoms to physician: If no improvement of UTI discomfort, signs or symptoms 48 hours after initiation of treatment and if adverse effects occur.
• Advise patient that drug may cause drowsiness or dizziness and to use caution while driving or performing other tasks requiring mental alertness.
• Caution patient to avoid exposure to ultraviolet light and sunlight and to use sunscreen or wear protective clothing and to use sunglasses when outdoors. Explain that photosensitivity may last up to 3 mo after last dose.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.